The estimated Net Worth of Curtis Hecht is at least 987 千$ dollars as of 6 July 2017. Mr. Hecht owns over 700 units of Calithera Biosciences Inc stock worth over 797$ and over the last 10 years he sold CALA stock worth over 50,765$. In addition, he makes 935,012$ as Chief Business Officer at Calithera Biosciences Inc.
Curtis has made over 7 trades of the Calithera Biosciences Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 700 units of CALA stock worth 12,600$ on 6 July 2017.
The largest trade he's ever made was exercising 2,000 units of Calithera Biosciences Inc stock on 20 August 2015 worth over 5,280$. On average, Curtis trades about 403 units every 43 days since 2015. As of 6 July 2017 he still owns at least 15,940 units of Calithera Biosciences Inc stock.
You can see the complete history of Mr. Hecht stock trades at the bottom of the page.
Curtis C. Hecht serves as Chief Business Officer of the Company. Mr. Hecht joined Calithera in April 2014 and currently serves as our Chief Business Officer. He has over 20 years of pharmaceutical research and development, commercialization, corporate strategy and business development experience, and has led or supported over $50 billion in strategic transactions. From September 2013 to April 2014, Mr. Hecht served as Vice President of Business Development at inVentiv Health, a global healthcare commercialization and consulting services company. Since 2011, Mr. Hecht has also served as a Partner at DNA Ink, a life sciences business development and strategy consulting firm. Prior to that, Mr. Hecht served in a number of roles at Genentech and Hoffmann La-Roche Inc., including Global Alliance Director, where he managed aspects of the Roche-Genentech collaboration, was a member of the Joint Development and Operations Committee with oversite of the joint development of Herceptin®, Avastin®, Rituxan®, Erivedge®, Kadcyla®, and Tarceva®, and was core team member in Roche’s $46.8 billion acquisition of Genentech in March 2009. As Director of Global Business Development, he evaluated and negotiated oncology licensing and M&A transactions. As Director of Marketing, he planned and executed the commercial launch of Xeloda® in adjuvant colorectal cancer and broadly managed brand promotions. Mr. Hecht received a B.S. in Chemistry with a concentration in Physics from California State University, Sacramento, and an MBA with concentrations in Marketing, Strategy, and Finance from Carnegie Mellon University, Tepper School of Business.
As the Chief Business Officer of Calithera Biosciences Inc, the total compensation of Curtis Hecht at Calithera Biosciences Inc is 935,012$. There are 3 executives at Calithera Biosciences Inc getting paid more, with Susan Molineaux having the highest compensation of 2,209,840$.
Curtis Hecht is 49, he's been the Chief Business Officer of Calithera Biosciences Inc since 2018. There are 14 older and 7 younger executives at Calithera Biosciences Inc. The oldest executive at Calithera Biosciences Inc is H. Ward Wolff, 71, who is the Independent Director.
Curtis's mailing address filed with the SEC is C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD. #200, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 10 years, insiders at Calithera Biosciences Inc have traded over 23,150,153$ worth of Calithera Biosciences Inc stock and bought 7,859,025 units worth 49,155,939$ . The most active insiders traders include Partners L P/Ilbiotechnolog...、Capital Partners Gp, L.L.C....、Deepika Pakianathan. On average, Calithera Biosciences Inc executives and independent directors trade stock every 43 days with the average trade being worth of 8,053$. The most recent stock trade was executed by Deepika Pakianathan on 27 January 2023, trading 121,333 units of CALA stock currently worth 47,320$.
calithera is focused on discovering and developing first-in-class small molecule drugs that slow tumor growth through controlling key metabolic pathways in the tumor and immune cells. tumor metabolism and tumor immunology are promising new interrelated fields for cancer drug discovery. recent clinical successes have demonstrated the potential to slow abnormal cell growth and create fundamentally new therapies for cancer patients. our investigational onco-metabolism medicines take advantage of the different metabolic requirements of tumor cells and cancer-fighting immune cells. calithera’s discovery and development efforts are focused on solid tumors for which new treatments are urgently needed. we are currently developing our lead candidate in phase 2 trials in patients with renal cell carcinoma, triple negative breast cancer. targeting cancer, differently. our onco-metabolism approach brings an enhanced perspective to cancer.
Calithera Biosciences Inc executives and other stock owners filed with the SEC include: